Updating the study protocol: Insight 46 – a longitudinal neuroscience sub-study of the MRC National Survey of Health and Development – phases 2 and 3.

Updating the study protocol: Insight 46 – a longitudinal neuroscience sub-study of the MRC National Survey of Health and Development – phases 2 and 3.

Publication date: Jan 23, 2024

Although age is the biggest known risk factor for dementia, there remains uncertainty about other factors over the life course that contribute to a person’s risk for cognitive decline later in life. Furthermore, the pathological processes leading to dementia are not fully understood. The main goals of Insight 46-a multi-phase longitudinal observational study-are to collect detailed cognitive, neurological, physical, cardiovascular, and sensory data; to combine those data with genetic and life-course information collected from the MRC National Survey of Health and Development (NSHD; 1946 British birth cohort); and thereby contribute to a better understanding of healthy ageing and dementia. Phase 1 of Insight 46 (2015-2018) involved the recruitment of 502 members of the NSHD (median age = 70. 7 years; 49% female) and has been described in detail by Lane and Parker et al. 2017. The present paper describes phase 2 (2018-2021) and phase 3 (2021-ongoing). Of the 502 phase 1 study members who were invited to a phase 2 research visit, 413 were willing to return for a clinic visit in London and 29 participated in a remote research assessment due to COVID-19 restrictions. Phase 3 aims to recruit 250 study members who previously participated in both phases 1 and 2 of Insight 46 (providing a third data time point) and 500 additional members of the NSHD who have not previously participated in Insight 46. The NSHD is the oldest and longest continuously running British birth cohort. Members of the NSHD are now at a critical point in their lives for us to investigate successful ageing and key age-related brain morbidities. Data collected from Insight 46 have the potential to greatly contribute to and impact the field of healthy ageing and dementia by combining unique life course data with longitudinal multiparametric clinical, imaging, and biomarker measurements. Further protocol enhancements are planned, including in-home sleep measurements and the engagement of participants through remote online cognitive testing. Data collected are and will continue to be made available to the scientific community.

Open Access PDF

Concepts Keywords
Dementia Ageing
Female Alzheimer’s disease
London Birth cohort
Neuroscience Cognition
Life course
Magnetic resonance imaging
Positron emission tomography
Vascular disease


Type Source Name
disease VO protocol
disease MESH dementia
disease MESH uncertainty
disease MESH cognitive decline
disease MESH pathological processes
drug DRUGBANK Tropicamide
disease MESH COVID-19
disease VO time
disease MESH morbidities
pathway REACTOME Reproduction
drug DRUGBANK Montelukast
disease MESH Alzheimer’s disease
disease MESH Vascular disease
disease MESH inflammation
drug DRUGBANK Trestolone
disease IDO blood
drug DRUGBANK Coenzyme M
disease IDO symptom
drug DRUGBANK Pentaerythritol tetranitrate
disease VO document
disease MESH claustrophobia
disease VO population
drug DRUGBANK Etoperidone
disease IDO production
drug DRUGBANK Methylergometrine
disease VO Sfs
drug DRUGBANK Esomeprazole
disease MESH strokes
disease IDO quality
drug DRUGBANK Albendazole
disease VO device
disease VO volume
disease MESH delirium
disease MESH violence
drug DRUGBANK Ilex paraguariensis leaf
disease IDO history
drug DRUGBANK Isoxaflutole
drug DRUGBANK Medical air
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Silver
drug DRUGBANK Gold
drug DRUGBANK Copper
drug DRUGBANK Zinc
drug DRUGBANK Ranitidine
disease MESH Sleepiness
disease MESH daytime sleepiness
disease MESH sleep quality
disease MESH sleep latency
drug DRUGBANK Aspartame
disease VO frequency
disease MESH bleeding
disease MESH insomnia
disease MESH Contraindications
disease MESH tonsillar hernia
drug DRUGBANK Acetylsalicylic acid
drug DRUGBANK Lidocaine
disease MESH allergy
disease IDO site
disease MESH backache
disease MESH infection
drug DRUGBANK Chlorhexidine
drug DRUGBANK Ethanol
drug DRUGBANK L-Isoleucine
drug DRUGBANK Edetic Acid
drug DRUGBANK Urea
drug DRUGBANK Creatinine
drug DRUGBANK Cyanocobalamin
drug DRUGBANK Folic Acid
disease VO Hormone
disease VO storage
drug DRUGBANK 5-amino-1 3 4-thiadiazole-2-thiol
disease VO injection
disease IDO susceptibility
disease MESH incidental findings
drug DRUGBANK Flunarizine
disease VO Gap
drug DRUGBANK Pixantrone
disease VO adverse event
disease MESH stenosis
drug DRUGBANK Quinine
disease MESH osteopenia
disease MESH osteoporosis
disease MESH abnormalities
disease MESH Left ventricular hypertrophy
disease MESH Sinus arrhythmia
disease MESH Atrial fibrillation
disease MESH Bundle branch block
disease MESH Pulmonary hypertension
disease MESH thrombus
disease MESH congenital heart disease
disease MESH Carotid artery stenosis
disease MESH atheromatous plaques
disease MESH Lymphadenopathy
disease MESH incoordination
disease MESH gait
drug DRUGBANK Ethionamide
disease MESH Neurodegenerative Disease
drug DRUGBANK Water
disease VO USA
disease MESH Death
disease MESH Vascular Dementia
disease MESH nominal dysphasia
drug DRUGBANK Oxygen
drug DRUGBANK Carboxyamidotriazole
disease MESH REM sleep behavior disorder
disease MESH frontotemporal dementia
disease MESH COPD
disease MESH asthma
pathway KEGG Asthma
disease MESH Cerebrovascular Disease

Original Article

(Visited 1 times, 1 visits today)